1
|
Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, Bouguetoch V, Marquès MA, Velazquez A, Viguerie N, Tavernier G, Arner P, Rydén M, Langin D, Sioufi N, Nasser M, Cabou C, Najib S, Martinez LO. P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. JCI Insight 2024; 9:e175623. [PMID: 38470490 DOI: 10.1172/jci.insight.175623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 03/05/2024] [Indexed: 03/13/2024] Open
Abstract
Excessive lipolysis in white adipose tissue (WAT) leads to insulin resistance (IR) and ectopic fat accumulation in insulin-sensitive tissues. However, the impact of Gi-coupled receptors in restraining adipocyte lipolysis through inhibition of cAMP production remained poorly elucidated. Given that the Gi-coupled P2Y13 receptor (P2Y13-R) is a purinergic receptor expressed in WAT, we investigated its role in adipocyte lipolysis and its effect on IR and metabolic dysfunction-associated steatotic liver disease (MASLD). In humans, mRNA expression of P2Y13-R in WAT was negatively correlated to adipocyte lipolysis. In mice, adipocytes lacking P2Y13-R displayed higher intracellular cAMP levels, indicating impaired Gi signaling. Consistently, the absence of P2Y13-R was linked to increased lipolysis in adipocytes and WAT explants via hormone-sensitive lipase activation. Metabolic studies indicated that mice lacking P2Y13-R showed a greater susceptibility to diet-induced IR, systemic inflammation, and MASLD compared with their wild-type counterparts. Assays conducted on precision-cut liver slices exposed to WAT conditioned medium and on liver-specific P2Y13-R-knockdown mice suggested that P2Y13-R activity in WAT protects from hepatic steatosis, independently of liver P2Y13-R expression. In conclusion, our findings support the idea that targeting adipose P2Y13-R activity may represent a pharmacological strategy to prevent obesity-associated disorders, including type 2 diabetes and MASLD.
Collapse
Affiliation(s)
- Thibaut Duparc
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Emilia Gore
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Guillaume Combes
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Diane Beuzelin
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | - Julie Pires Da Silva
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Vanessa Bouguetoch
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | | | - Ana Velazquez
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Nathalie Viguerie
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
| | - Geneviève Tavernier
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
| | - Peter Arner
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Mikael Rydén
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Dominique Langin
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
- Biochemistry Laboratory, Toulouse University Hospital, Toulouse, France
- Institut Universitaire de France (IUF), Paris, France
| | - Nabil Sioufi
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | - Mohamad Nasser
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Cendrine Cabou
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Souad Najib
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Laurent O Martinez
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
2
|
Martinez L, Gore E, Combes G, Cabou C, Duparc T. The GI-coupled P2Y13 receptor signaling inhibits lipolysis and protects from metabolic syndrome and associated liver diseases. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
3
|
Cabou C, Honorato P, Briceño L, Ghezali L, Duparc T, León M, Combes G, Frayssinhes L, Fournel A, Abot A, Masri B, Parada N, Aguilera V, Aguayo C, Knauf C, González M, Radojkovic C, Martinez LO. Pharmacological inhibition of the F 1 -ATPase/P2Y 1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation. Acta Physiol (Oxf) 2019; 226:e13268. [PMID: 30821416 DOI: 10.1111/apha.13268] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 02/14/2019] [Accepted: 02/22/2019] [Indexed: 12/12/2022]
Abstract
AIM The contribution of apolipoprotein A1 (APOA1), the major apolipoprotein of high-density lipoprotein (HDL), to endothelium-dependent vasodilatation is unclear, and there is little information regarding endothelial receptors involved in this effect. Ecto-F1 -ATPase is a receptor for APOA1, and its activity in endothelial cells is coupled to adenosine diphosphate (ADP)-sensitive P2Y receptors (P2Y ADP receptors). Ecto-F1 -ATPase is involved in APOA1-mediated cell proliferation and HDL transcytosis. Here, we investigated the effect of lipid-free APOA1 and the involvement of ecto-F1 -ATPase and P2Y ADP receptors on nitric oxide (NO) synthesis and the regulation of vascular tone. METHOD Nitric oxide synthesis was assessed in human endothelial cells from umbilical veins (HUVECs) and isolated mouse aortas. Changes in vascular tone were evaluated by isometric force measurements in isolated human umbilical and placental veins and by assessing femoral artery blood flow in conscious mice. RESULTS Physiological concentrations of lipid-free APOA1 enhanced endothelial NO synthesis, which was abolished by inhibitors of endothelial nitric oxide synthase (eNOS) and of the ecto-F1 -ATPase/P2Y1 axis. Accordingly, APOA1 inhibited vasoconstriction induced by thromboxane A2 receptor agonist and increased femoral artery blood flow in mice. These effects were blunted by inhibitors of eNOS, ecto-F1 -ATPase and P2Y1 receptor. CONCLUSIONS Using a pharmacological approach, we thus found that APOA1 promotes endothelial NO production and thereby controls vascular tone in a process that requires activation of the ecto-F1 -ATPase/P2Y1 pathway by APOA1. Pharmacological targeting of this pathway with respect to vascular diseases should be explored.
Collapse
Affiliation(s)
- Cendrine Cabou
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
- Department of Human Physiology, Faculty of Pharmacy University Paul Sabatier Toulouse France
| | - Paula Honorato
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Luis Briceño
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Lamia Ghezali
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Thibaut Duparc
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Marcelo León
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Guillaume Combes
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Laure Frayssinhes
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Audren Fournel
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Anne Abot
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Bernard Masri
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Nicol Parada
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Valeria Aguilera
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Claudio Aguayo
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health) Chillan Chile
| | - Claude Knauf
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Marcelo González
- Group of Research and Innovation in Vascular Health (GRIVAS Health) Chillan Chile
- Vascular Physiology Laboratory, Department of Physiology, Faculty of Biological Sciences, and Department of Obstetrics and Gynecology, Faculty of Medicine Universidad de Concepción Concepción Chile
| | - Claudia Radojkovic
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Laurent O. Martinez
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| |
Collapse
|
4
|
Valéra MC, Noirrit-Esclassan E, Dupuis M, Fontaine C, Lenfant F, Briaux A, Cabou C, Garcia C, Lairez O, Foidart JM, Payrastre B, Arnal JF. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Mol Cell Endocrinol 2018; 477:132-139. [PMID: 29928930 DOI: 10.1016/j.mce.2018.06.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 04/13/2018] [Accepted: 06/16/2018] [Indexed: 01/27/2023]
Abstract
Estetrol (E4) is a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, and the physiological role of this hormone is unknown. Interestingly, E4 was recently evaluated in preclinical and phase II-III clinical studies in combination with a progestin, with the advantage to not increase the circulating level of coagulation factors, at variance to oral estradiol or ethinylestradiol. Here, we evaluated the effect of E4 on hemostasis and thrombosis in mouse. Following chronic E4 treatment, mice exhibited a prolonged tail-bleeding time and were protected from arterial and also venous thrombosis in vivo. In addition, E4 treatment decreased ex vivo thrombus growth on collagen under arterial flow conditions. We recently showed that E4 activates uterine epithelial proliferation through nuclear estrogen receptor (ER) α. To analyze the impact of nuclear ERα actions on hemostasis and thrombosis, we generated hematopoietic chimera with bone marrow cells deficient for nuclear ERα. E4-induced protection against thromboembolism was significantly reduced in the absence of hematopoietic nuclear ERα activation, while the increased tail-bleeding time was not impacted by this deletion. In addition to its "liver friendly" profile described in women, our data shows that E4 has anti-thrombotic properties in various mouse models. Altogether, the natural fetal estrogen E4 could represent an attractive alternative to classic estrogens in oral contraception and treatment of menopause.
Collapse
Affiliation(s)
- Marie-Cécile Valéra
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France; Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
| | - Emmanuelle Noirrit-Esclassan
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France; Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
| | - Marion Dupuis
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Coralie Fontaine
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Françoise Lenfant
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Anne Briaux
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Cendrine Cabou
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Cedric Garcia
- Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France
| | - Olivier Lairez
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France
| | - Jean-Michel Foidart
- Laboratory of Tumor and Development Biology GIGA-Cancer, Institute of Pathology, University of Liège, CHU-B23, B-4000, Liège, Belgium
| | - Bernard Payrastre
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France; Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France
| | - Jean-François Arnal
- I2MC, Inserm U1048, CHU de Toulouse and Université de ToulouseToulouse, France.
| |
Collapse
|
5
|
Laurent PA, Hechler B, Solinhac R, Ragab A, Cabou C, Anquetil T, Severin S, Denis CV, Mangin PH, Vanhaesebroeck B, Payrastre B, Gratacap MP. Impact of PI3Kα (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol 2018; 38:2041-2053. [PMID: 30354258 DOI: 10.1161/atvbaha.118.311410] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective- PI3Kα (phosphoinositide 3-kinase alpha) is a therapeutic target in oncology, but its role in platelets and thrombosis remains ill characterized. In this study, we have analyzed the role of PI3Kα in vitro, ex vivo, and in vivo in 2 models of arterial thrombosis. Approach and Results- Using mice selectively deficient in p110α in the megakaryocyte lineage and isoform-selective inhibitors, we confirm that PI3Kα is not mandatory but participates to thrombus growth over a collagen matrix at arterial shear rate. Our data uncover a role for PI3Kα in low-level activation of the GP (glycoprotein) VI-collagen receptor by contributing to ADP secretion and in turn full activation of PI3Kβ and Akt/PKB (protein kinase B). This effect was no longer observed at high level of GP VI agonist concentration. Our study also reveals that over a vWF (von Willebrand factor) matrix, PI3Kα regulates platelet stationary adhesion contacts under arterial flow through its involvement in the outside-in signaling of vWF-engaged αIIbβ3 integrin. In vivo, absence or inhibition of PI3Kα resulted in a modest but significant decrease in thrombus size after superficial injuries of mouse mesenteric arteries and an increased time to arterial occlusion after carotid lesion, without modification in the tail bleeding time. Considering the more discrete and nonredundant role of PI3Kα compared with PI3Kβ, selective PI3Kα inhibitors are unlikely to increase the bleeding risk at least in the absence of combination with antiplatelet drugs or thrombopenia. Conclusions- This study provides mechanistic insight into the role of PI3Kα in platelet activation and arterial thrombosis.
Collapse
Affiliation(s)
- Pierre-Alexandre Laurent
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Béatrice Hechler
- INSERM, EFS Grand Est, BPPS UMR-S 949, FMTS, Université de Strasbourg, France (B.H., P.H.M.)
| | - Romain Solinhac
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Ashraf Ragab
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Cendrine Cabou
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Typhaine Anquetil
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Sonia Severin
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| | - Cécile V Denis
- INSERM, UMR-S 1176, University of Paris-Sud, Université Paris-Saclay, France (C.V.D.)
| | - Pierre H Mangin
- INSERM, EFS Grand Est, BPPS UMR-S 949, FMTS, Université de Strasbourg, France (B.H., P.H.M.)
| | - Bart Vanhaesebroeck
- Cell Signaling, UCL Cancer Institute, University College London, United Kingdom (B.V.)
| | - Bernard Payrastre
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
- CHU de Toulouse, Laboratoire d'Hématologie, France (B.P.)
| | - Marie-Pierre Gratacap
- From the INSERM, UMR-S1048, Université Toulouse III, France (P.-A.L., R.S., A.R., C.C., T.A., S.S., B.P., M.-P.G.)
| |
Collapse
|
6
|
Castaing-Berthou A, Malet N, Radojkovic C, Cabou C, Gayral S, Martinez LO, Laffargue M. PI3Kβ Plays a Key Role in Apolipoprotein A-I-Induced Endothelial Cell Proliferation Through Activation of the Ecto-F1-ATPase/P2Y1 Receptors. Cell Physiol Biochem 2017; 42:579-593. [PMID: 28578353 DOI: 10.1159/000477607] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Accepted: 04/05/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS High-density lipoproteins (HDL) exert multiple cardioprotective functions on the arterial wall, including the promotion of endothelial cell survival and proliferation. Among mechanism contributing to endothelial protection, it has been reported that apolipoprotein A-I (apoA-I), the major protein in HDL, binds and activates the endothelial ecto-F1-ATPase receptor. This generates extracellular ADP, which in turn promotes endothelial cell survival. In this study we aimed to further investigate the signaling pathway involved downstream of apoA-I-induced ecto-F1-ATPase activation. METHODS In human umbilical vein endothelial cells (HUVECs), pharmacological and gene silencing approaches were used to study pathways involved downstream ecto-F1-ATPase activation by apoA-I. RESULTS ApoA-I and HDL both induced Akt phosphorylation. F1-ATPase inhibitors such as inhibitory factor 1 and oligomycin completely blocked apoA-I-induced Akt phosphorylaton and significantly blocked HDL-induced phosphorylation, indicating that this signaling pathway is dependent on ecto-F1-ATPase activation by apoA-I. Further, we were able to specify roles for the P2Y1-ADPreceptor and the PI3Kβ isoform in this pathway since pharmacological inhibition and silencing of these proteins dramatically inhibited apoA-I-induced Akt phosphorylation and cell proliferation. CONCLUSION Altogether, these data highlight a key role of the P2Y1/PI3Kβ axis in endothelial cell proliferation downstream of ecto-F1-ATPase activation by apoA-I. Pharmacological targeting of this pathway could represent a promising approach to enhance vascular endothelial protection.
Collapse
Affiliation(s)
- Audrey Castaing-Berthou
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| | - Nicole Malet
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| | - Claudia Radojkovic
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepción, Concepción, Chile
| | - Cendrine Cabou
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| | - Stéphanie Gayral
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| | - Laurent Olivier Martinez
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| | - Muriel Laffargue
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.,University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France
| |
Collapse
|
7
|
Valéra MC, Fontaine C, Lenfant F, Cabou C, Guillaume M, Smirnova N, Kim SH, Chambon P, Katzenellenbogen JA, Katzenellenbogen BS, Payrastre B, Arnal JF. Protective Hematopoietic Effect of Estrogens in a Mouse Model of Thrombosis: Respective Roles of Nuclear Versus Membrane Estrogen Receptor α. Endocrinology 2015; 156:4293-301. [PMID: 26280130 PMCID: PMC4606746 DOI: 10.1210/en.2015-1522] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
We recently reported that chronic 17β-estradiol (E2) treatment in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism via the hematopoietic estrogen receptor alpha (ERα), and independently of ERβ. Here, we have explored the respective roles of membrane vs nuclear actions of ERα in this process, using: 1) the selective activator of membrane ERα: estrogen dendrimer conjugate, and 2) mouse models with mutations in ERα. The selective targeting of activation function 2 of ERα provides a model of nuclear ERα loss-of-function, whereas mutation of the ERα palmitoylation site leads to a model of membrane ERα deficiency. The combination of pharmacological and genetic approaches including hematopoietic chimera mice demonstrated that absence of either membrane or nuclear ERα activation in bone marrow does not prevent the prolongation of the tail-bleeding time, suggesting a redundancy of these two functions for this E2 effect. In addition, although hematopoietic membrane ERα is neither sufficient nor necessary to protect E2-treated mice from collagen/epinephrine-induced thromboembolism, the protection against death-induced thromboembolism is significantly reduced in the absence of hematopoietic nuclear ERα activation. Overall, this study emphasizes that hematopoietic cells (likely megakaryocytes and possibly immune cells) constitute an important target in the antithrombotic effects of estrogens, and delineate for the first time in vivo the respective roles of membrane vs nuclear ERα effects, with a prominent role of the latter.
Collapse
Affiliation(s)
- Marie-Cécile Valéra
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Coralie Fontaine
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Françoise Lenfant
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Cendrine Cabou
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Maeva Guillaume
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Natalia Smirnova
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Sung Hoon Kim
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Pierre Chambon
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - John A Katzenellenbogen
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Benita S Katzenellenbogen
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Bernard Payrastre
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| | - Jean-François Arnal
- INSERM U1048 and Université Toulouse III I2MC (M.-C.V., C.F., F.L., C.C., M.G., N.S., B.P., J.-F.A.), Toulouse, 31432 France; Faculté de Chirurgie Dentaire (M.-C.V.), Université de Toulouse III, Toulouse, 31432 France; Department of Chemistry (H.H.K., J.A.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; Institut de Génétique et de Biologie Moléculaire et Cellulaire (P.C.), Collège de France, Université de Strasbourg, Illkirch, 67400 France; Department of Physiology and Cell Biology (B.S.K.), University of Illinois at Urbana-Champaign, Urbana, IL 61801; and Laboratoire d'Hématologie (B.P.), Centre Hospitalier Universitaire de Toulouse, Toulouse, 31432 France
| |
Collapse
|
8
|
Le HL, Jullian V, Claparols C, Vansteelandt M, Haddad M, Cabou C, Deharo E, Fabre N. Development and validation of liquid chromatography combined with tandem mass spectrometry methods for the quantitation of simalikalactone E in extracts of Quassia amara L. and in mouse blood. Phytochem Anal 2015; 26:111-118. [PMID: 25431121 DOI: 10.1002/pca.2542] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 09/02/2014] [Accepted: 09/04/2014] [Indexed: 06/04/2023]
Abstract
INTRODUCTION Simalikalactone E (SkE) from Quassia amara, has been proved to be a valuable anti-malarial and anti-cancer compound. As SkE is very scarce, methods of quantitation are needed in order to optimise its isolation process and to determine pharmacokinetic data. OBJECTIVE To validate methods using liquid chromatography coupled to mass spectrometry for the quantitation of SkE in plant extracts and in biological fluids. METHODS High- and ultrahigh-performance liquid chromatography (UHPLC) coupled to ion trap mass spectrometry (MS) with single ion monitoring detection and to triple quadrupole-linear ion trap tandem mass spectrometry with multiple reaction monitoring detection methods were developed. Validation procedure was realised according to the International Conference on Harmonisation guideline. Methanol extracts of dried Quassia amara leaves, and mouse-blood samples obtained after various routes of administration, were analysed for SkE. RESULTS Methods were validated and gave similar results regarding the content of SkE expressed per kilogram of dry leaves in the traditional decoction (160 ± 12 mg/kg) and in the methanol extract (93 ± 2 mg/kg). The recovery of the analyte from mouse blood ranged from 80.7 to 119.8%. Simalikalactone E was only detected using UHPLC-MS/MS (0.2 ± 0.03 mg/L) in mouse blood after intravenous injection: none was detected following intraperitoneal or oral gavage administration of SkE. CONCLUSION The LC-MS methods were used for the quantitation of SkE in plant extracts and in mouse blood. These methods open the way for further protocol optimisation of SkE extraction and the determination of its pharmacokinetic data.
Collapse
Affiliation(s)
- Hong Luyen Le
- Université de Toulouse, UPS, UMR 152 Pharma-DEV, Université Toulouse 3, Faculté des Sciences Pharmaceutiques, F-31062, Toulouse cedex 09, France; Institut de Recherche pour le Développement (IRD), UMR 152 Pharma-DEV, F-31062, Toulouse cedex 09, France
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Serhan N, Cabou C, Verdier C, Lichtenstein L, Malet N, Perret B, Laffargue M, Martinez LO. Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion. Biochim Biophys Acta Mol Cell Biol Lipids 2012; 1831:719-25. [PMID: 23266391 DOI: 10.1016/j.bbalip.2012.12.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Revised: 12/10/2012] [Accepted: 12/12/2012] [Indexed: 11/16/2022]
Abstract
High level of high-density lipoprotein cholesterol (HDL-cholesterol) is inversely correlated to the risk of atherosclerotic cardiovascular disease. The protective effect of HDL is mostly attributed to their metabolic functions in reverse cholesterol transport (RCT), a process whereby excess cell cholesterol is taken up from peripheral cells and processed in HDL particles, and is later delivered to the liver for further metabolism and bile excretion. We have previously demonstrated that P2Y13 receptor is critical for RCT and that intravenous bolus injection of cangrelor (AR-C69931MX), a partial agonist of P2Y13 receptor, can stimulate hepatic HDL uptake and subsequent lipid biliary secretion without any change in plasma lipid levels. In the present study, we investigated the effect of longer-term treatment with cangrelor on lipoprotein metabolism in mice. We observed that continuous delivery of cangrelor at a rate of 35μg/day/kg body weight for 3days markedly decreased plasma HDL-cholesterol level, by increasing the clearance of HDL particles by the liver. These effects were correlated to an increase in the rate of biliary bile acid secretion. An increased expression of SREBP-regulated genes of cholesterol metabolism was also observed without any change of hepatic lipid levels as compared to non-treated mice. Thus, 3-day cangrelor treatment markedly increases the flux of HDL-cholesterol from the plasma to the liver for bile acid secretion. Taken together our results suggest that P2Y13 appears a promising target for therapeutic intervention aimed at preventing or reducing cardiovascular risk.
Collapse
Affiliation(s)
- Nizar Serhan
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Glucagon-like peptide 1 (GLP-1) is a gut hormone which directly binds to the GLP-1 receptor located at the surface of the pancreatic β-cells to enhance glucose-induced insulin secretion. In addition to its pancreatic effects, GLP-1 can induce metabolic actions by interacting with its receptors expressed on nerve cells in the gut and the brain. GLP-1 can also be considered as a neuropeptide synthesized by neuronal cells in the brain stem that release the peptide directly into the hypothalamus. In this environment, GLP-1 is assumed to control numerous metabolic and cardiovascular functions such as insulin secretion, glucose production and utilization, and arterial blood flow. However, the exact roles of these two locations in the regulation of glucose homeostasis are not well understood. In this review, we highlight the latest experimental data supporting the role of the gut-brain and brain-periphery axes in the control of glucose homeostasis. We also focus our attention on the relevance of β-cell and brain cell targeting by gut GLP-1 for the regulation of glucose homeostasis. In addition to its action on β-cells, we find that understanding the physiological role of GLP-1 will help to develop GLP-1-based therapies to control glycemia in type 2 diabetes by triggering the gut-brain axis or the brain directly. This pleiotropic action of GLP-1 is an important concept that may help to explain the observation that, during their treatment, type 2 diabetic patients can be identified as 'responders' and 'non-responders'.
Collapse
Affiliation(s)
- Cendrine Cabou
- INSERM (Institut National de la Sante et de la Recherche Medicale), U1048, Institute of Metabolic and Cardiovascular Diseases Rangueil, University of Toulouse III (Paul-Sabatier), Toulouse, France
| | | |
Collapse
|
11
|
Abstract
OBJECTIVE Glucagon-like peptide 1 (GLP-1) is a gut-brain hormone that regulates food intake, energy metabolism, and cardiovascular functions. In the brain, through a currently unknown molecular mechanism, it simultaneously reduces femoral artery blood flow and muscle glucose uptake. By analogy to pancreatic β-cells where GLP-1 activates protein kinase C (PKC) to stimulate insulin secretion, we postulated that PKC enzymes would be molecular targets of brain GLP-1 signaling that regulate metabolic and vascular function. RESEARCH DESIGN AND METHODS We used both genetic and pharmacological approaches to investigate the role of PKC isoforms in brain GLP-1 signaling in the conscious, free-moving mouse simultaneous with metabolic and vascular measurements. RESULTS In normal wild-type (WT) mouse brain, the GLP-1 receptor (GLP-1R) agonist exendin-4 selectively promotes translocation of PKC-δ (but not -βII, -α, or -ε) to the plasma membrane. This translocation is blocked in Glp1r(-/-) mice and in WT mice infused in the brain with exendin-9, an antagonist of the GLP-1R. This mechanism coordinates both blood flow in the femoral artery and whole-body insulin sensitivity. Consequently, in hyperglycemic, high-fat diet-fed diabetic mice, hypothalamic PKC-δ activity was increased and its pharmacological inhibition improved both insulin-sensitive metabolic and vascular phenotypes. CONCLUSIONS Our studies show that brain GLP-1 signaling activates hypothalamic glucose-dependent PKC-δ to regulate femoral artery blood flow and insulin sensitivity. This mechanism is attenuated during the development of experimental hyperglycemia and may contribute to the pathophysiology of type 2 diabetes.
Collapse
Affiliation(s)
- Cendrine Cabou
- INSERM U1048, Institute of Metabolic and Cardiovascular Diseases, Rangueil, Université Paul-Sabatier, Toulouse, France
- Faculty of Pharmacy, Chemin des Maraîchers, Toulouse, France
| | - Christelle Vachoux
- INSERM U1048, Institute of Metabolic and Cardiovascular Diseases, Rangueil, Université Paul-Sabatier, Toulouse, France
- Faculty of Pharmacy, Chemin des Maraîchers, Toulouse, France
| | - Gérard Campistron
- INSERM U1048, Institute of Metabolic and Cardiovascular Diseases, Rangueil, Université Paul-Sabatier, Toulouse, France
- Faculty of Pharmacy, Chemin des Maraîchers, Toulouse, France
| | - Daniel J. Drucker
- Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Rémy Burcelin
- INSERM U1048, Institute of Metabolic and Cardiovascular Diseases, Rangueil, Université Paul-Sabatier, Toulouse, France
- Corresponding author: Rémy Burcelin,
| |
Collapse
|
12
|
Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011; 152:3018-29. [PMID: 21673098 DOI: 10.1210/en.2011-0286] [Citation(s) in RCA: 124] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Inhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose-induced insulin secretion. However, the DPP-4 enzyme is highly expressed on the surface of intestinal epithelial cells; hence, the role of intestinal vs. systemic DPP-4 remains unclear. To analyze mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice, we administered low oral doses of the DPP-4 inhibitor sitagliptin that selectively reduced DPP-4 activity in the intestine. Glp1r(-/-) and Gipr(-/-) mice were studied and glucagon-like peptide (GLP)-1 receptor (GLP-1R) signaling was blocked by an i.v. infusion of the corresponding receptor antagonist exendin (9-39). The role of the dipeptides His-Ala and Tyr-Ala as DPP-4-generated GLP-1 and glucose-dependent insulinotropic peptide (GIP) degradation products was studied in vivo and in vitro on isolated islets. We demonstrate that very low doses of oral sitagliptin improve glucose tolerance and plasma insulin levels with selective reduction of intestinal but not systemic DPP-4 activity. The glucoregulatory action of sitagliptin was associated with increased vagus nerve activity and was diminished in wild-type mice treated with the GLP-1R antagonist exendin (9-39) and in Glp1r(-/-) and Gipr(-/-) mice. Furthermore, the dipeptides liberated from GLP-1 (His-Ala) and GIP (Tyr-Ala) deteriorated glucose tolerance, reduced insulin, and increased portal glucagon levels. The predominant mechanism through which DPP-4 inhibitors regulate glycemia involves local inhibition of intestinal DPP-4 activity, activation of incretin receptors, reduced liberation of bioactive dipeptides, and activation of the gut-to-pancreas neural axis.
Collapse
Affiliation(s)
- Aurélie Waget
- Institut de Recherche sur les Maladies Métaboliques et Cardiovasculaires de l'Hôpital Rangueil, Inserm U1048, BP 84225, 31432 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Burcelin R, Serino M, Cabou C. A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. Curr Opin Pharmacol 2009; 9:744-52. [DOI: 10.1016/j.coph.2009.09.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 08/18/2009] [Accepted: 09/07/2009] [Indexed: 10/20/2022]
|
14
|
Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Pénicaud L, Drucker DJ, Magnan C, Burcelin R. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008; 57:2577-87. [PMID: 18633100 PMCID: PMC2551665 DOI: 10.2337/db08-0121] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2008] [Accepted: 07/08/2008] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To ascertain the importance and mechanisms underlying the role of brain glucagon-like peptide (GLP)-1 in the control of metabolic and cardiovascular function. GLP-1 is a gut hormone secreted in response to oral glucose absorption that regulates glucose metabolism and cardiovascular function. GLP-1 is also produced in the brain, where its contribution to central regulation of metabolic and cardiovascular homeostasis remains incompletely understood. RESEARCH DESIGN AND METHODS Awake free-moving mice were infused with the GLP-1 receptor agonist exendin-4 (Ex4) into the lateral ventricle of the brain in the basal state or during hyperinsulinemic eu-/hyperglycemic clamps. Arterial femoral blood flow, whole-body insulin-stimulated glucose utilization, and heart rates were continuously recorded. RESULTS A continuous 3-h brain infusion of Ex4 decreased femoral arterial blood flow and whole-body glucose utilization in the awake free-moving mouse clamped in a hyperinsulinemic-hyperglycemic condition, only demonstrating that this effect was strictly glucose dependent. However, the heart rate remained unchanged. The metabolic and vascular effects of Ex4 were markedly attenuated by central infusion of the GLP-1 receptor (GLP-1R) antagonist exendin-9 (Ex9) and totally abolished in GLP-1 receptor knockout mice. A correlation was observed between the metabolic rate and the vascular flow in control and Ex4-infused mice, which disappeared in Ex9 and GLP-1R knockout mice. Moreover, hypothalamic nitric oxide synthase activity and the concentration of reactive oxygen species (ROS) were also reduced in a GLP-1R-dependent manner, whereas the glutathione antioxidant capacity was increased. Central GLP-1 activated vagus nerve activity, and complementation with ROS donor dose-dependently reversed the effect of brain GLP-1 signaling on peripheral blood flow. CONCLUSIONS Our data demonstrate that central GLP-1 signaling is an essential component of circuits integrating cardiovascular and metabolic responses to hyperglycemia.
Collapse
Affiliation(s)
- Cendrine Cabou
- Institut National de la Santé et de la Recherche Médicale (INSERM), U858, Institute of Molecular Medicine Rangueil, Toulouse, France
- Université Toulouse III Paul-Sabatier, IFR31, Toulouse, France
- Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Gérard Campistron
- Institut National de la Santé et de la Recherche Médicale (INSERM), U858, Institute of Molecular Medicine Rangueil, Toulouse, France
- Université Toulouse III Paul-Sabatier, IFR31, Toulouse, France
- Faculté des Sciences Pharmaceutiques, Toulouse, France
| | | | - Corinne Leloup
- Université Toulouse III Paul-Sabatier, IFR31, Toulouse, France
- UMR UPS-CNRS 5241, Toulouse, France
| | | | - Luc Pénicaud
- Université Toulouse III Paul-Sabatier, IFR31, Toulouse, France
- UMR UPS-CNRS 5241, Toulouse, France
| | - Daniel J. Drucker
- Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | - Rémy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), U858, Institute of Molecular Medicine Rangueil, Toulouse, France
- Université Toulouse III Paul-Sabatier, IFR31, Toulouse, France
| |
Collapse
|
15
|
Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Pénicaud L, Valet P, Burcelin R. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008; 149:4768-77. [PMID: 18556349 DOI: 10.1210/en.2008-0180] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Glucagon-like peptide-1 (GLP-1) is a peptide released by the intestine and the brain. We previously demonstrated that brain GLP-1 increases glucose-dependent hyperinsulinemia and insulin resistance. These two features are major characteristics of the onset of type 2 diabetes. Therefore, we investigated whether blocking brain GLP-1 signaling would prevent high-fat diet (HFD)-induced diabetes in the mouse. Our data show that a 1-month chronic blockage of brain GLP-1 signaling by exendin-9 (Ex9), totally prevented hyperinsulinemia and insulin resistance in HFD mice. Furthermore, food intake was dramatically increased, but body weight gain was unchanged, showing that brain GLP-1 controlled energy expenditure. Thermogenesis, glucose utilization, oxygen consumption, carbon dioxide production, muscle glycolytic respiratory index, UCP2 expression in muscle, and basal ambulatory activity were all increased by the exendin-9 treatment. Thus, we have demonstrated that in response to a HFD, brain GLP-1 signaling induces hyperinsulinemia and insulin resistance and decreases energy expenditure by reducing metabolic thermogenesis and ambulatory activity.
Collapse
Affiliation(s)
- Claude Knauf
- Institut de Medecine Moleculaire de Rangueil, Toulouse III University, Centre Hospitalier Universitaire Rangueil, BP84225, 31432 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
A Prospective pharmacovigilance survey of adverse drug reactions (ADRs) in pregnant women was performed in collaboration with gynaecologists and obstetricians of Midi-Pyrenees area (south west of france). The aim of the study was to evaluate the incidence of adverse drug reactions in pregnant women. The incidence of ADRs in pregnant women was low: 0.3%. Moreover, a retrospective pharmacoepidemiological study was conducted to characterize ADRs in pregnant women. Reports of ADRs collected in the Midi-Pyrenees pharmacovigilance centre from 1982 to 2002 were used: type of ADRs, drugs involved and potential risk factors were compared for pregnant women and for age-matched non pregnant women. Forty seven and 94 reports of ADRs were collected in pregnant and non-pregnant women respectively. Anaphylactic reactions were only observed in pregnant women (3 cases, p = 0.04). We observed 1 ADR related stillbirth (due to anaphylactic reaction) in pregnant women. Drugs for gynaecological and cardiovascular systems were more frequently involved in ADRs in pregnant women than in controls. ADRs mainly occurred during the third trimester of pregnancy. The incidence of ADRs is very low in pregnant women. However, one must pay attention on the risk of anaphylactic reactions in pregnant women.
Collapse
Affiliation(s)
- Isabelle Lacroix
- Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, EA 3696, Université de Toulouse, Faculté de Médecine, Toulouse, France.
| | | | | | | |
Collapse
|
17
|
Cabou C, Cani PD, Campistron G, Knauf C, Mathieu C, Sartori C, Amar J, Scherrer U, Burcelin R. Central insulin regulates heart rate and arterial blood flow: an endothelial nitric oxide synthase-dependent mechanism altered during diabetes. Diabetes 2007; 56:2872-7. [PMID: 17804761 DOI: 10.2337/db07-0115] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Central neural insulin regulates glucose homeostasis, but less is known about its cardiovascular effects. Endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) represents a molecular link between metabolic and cardiovascular disease. Its role in the central nervous system remains to be determined. We studied the effects of central insulin infusion on femoral arterial blood flow and heart rate in normal chow-fed, high-fat diet-fed diabetic, and eNOS-null mice. RESEARCH DESIGN AND METHODS We recorded heart rate and femoral blood flow (ultrasonic flow probe) during 3-h central insulin infusion in conscious, freely moving mice. To study the role of NO in this setting, we assessed total and phosphorylated eNOS in the hypothalamus and examined the effects of brain infusion of NO donors/NOS inhibitors on cardiovascular responsiveness to central insulin in these experimental mouse models. RESULTS In normal mice, central insulin rapidly increased heart rate by 30% and more progressively increased blood flow by 40%. In high-fat diet-fed mice, the cardiovascular effects of insulin were blunted and associated with a 50% reduction of the total and phosphorylated eNOS expression in the hypothalamus, suggesting a causal link. In line with this hypothesis, in eNOS-null mice and central N(G)-monomethyl-L-arginine-infused normal mice, the cardiovascular effects of insulin were abolished, whereas central NO donor infusion restored these effects in eNOS-null mice. In high-fat diet-fed mice, central NO donor infusion mimicked the cardiovascular responses evoked by central insulin in normal mice. CONCLUSIONS Central insulin has cardiovascular effects in conscious, freely moving mice that are mediated, at least in part, by central neural eNOS. These effects are impaired in insulin-resistant high-fat diet-fed mice.
Collapse
Affiliation(s)
- Cendrine Cabou
- Inserm U858, Institute of Molecular Medicine, IFR31, CHU Rangueil, BP 84225, 31432 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Cabou C, Lacroix I, Roncalli J, Elbaz M, Caillaux D, Damase-Michel C, Fauvel JM, Montastruc JL. [Myocardial infarction in a young female smoker taking oral contraception]. Arch Mal Coeur Vaiss 2006; 99:80-5. [PMID: 16479896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A 33 year old woman suffered a lateral myocardial infarction for the first time, and was treated by pre-hospital thrombolysis and secondary angioplasty on the diagonal artery. Fifteen days before the cardiac event she had undergone a left ovarian cyst excision and left salpingectomy for an ectopic pregnancy. She was a moderate smoker and had been taking a second-generation biphasic minidose oral contraceptive (ethinyl-estradiol 30-40mg and levonorgestrel 150-200 mg) for about ten years. Fifteen days before the myocardial infarction and due to the ectopic pregnancy she had changed to a combined monophasic minidose oral contraceptive pill containing ethinylestradiol (30 mg) and drospirenone (3 mg). The eventual outcome was favourable, with no complications. In this article we discuss the possible implications of the various factors (oral contraceptive, tobacco use, and surgical intervention) in this young woman with a myocardial infarction.
Collapse
Affiliation(s)
- C Cabou
- Service de pharmacologie clinique. Centre Midi-Pyrénées de pharmacovigilance, faculté de médecine, 37, allées Jules Guesde. 31073 Toulouse Cedex
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Cabou C, Bagheri H, Cantagrel A, Mazières B, Montastruc JL. Analyse rétrospective des effets indésirables de l’infliximab dans un service hospitalier de rhumatologie. Therapie 2003; 58:457-62. [PMID: 14682196 DOI: 10.2515/therapie:2003074] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Infliximab is a chimeric monoclonal antibody against human tumour necrosis factor-alpha (TNF alpha), and has received marketing authorization for the treatment of both rheumatoid arthritis (RA) and Crohn's disease. The aim of the present survey was to assess retrospectively adverse drug reactions (ADRs) in patients treated with infliximab for RA in a rheumatology department of the Toulouse University Hospital (Rangueil Hospital). Among 32 patients included in 2000 and 2001, 43 "expected" ADRs occurred in 21 patients (65.6%) [mean age 51.4 +/- 14.0 years]. In four patients (12.5%), ADRs were classified as "serious". In five other patients, they required the discontinuation of infliximab. We identified mainly infectious (n = 21), allergic (n = 3) and cardiovascular (n = 3) ADRs. Infectious ADRs were as follows: seven urinary infections, with a positive rechallenge (R+) in five; nine respiratory infections, with R+ in five; and five cutaneous infections. An acute rise in blood pressure occurred in three patients who had already been treated with antihypertensive drugs. The incidence of ADRs was as follows: respiratory 28.0%; urinary 22.0%; cutaneous 15.6%; allergic 9.4%; and cardiovascular 9.4%. In conclusion, our data allowed a quantitative and qualitative assessment of infliximab-induced ADRs. Further studies are required in order to improve knowledge regarding ADRs induced by long-term treatment with infliximab.
Collapse
Affiliation(s)
- Cendrine Cabou
- Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse, France
| | | | | | | | | |
Collapse
|
20
|
Cabou C, Lacroix I, Rista C, Rolland M, Chassaing N, Calvas P, Montastruc JL, Damase-Michel C. [Finger agenesis after in utero exposure to ketoconazole: a case report]. Therapie 2003; 58:172-4. [PMID: 12942862 DOI: 10.2515/therapie:2003028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|